In the latest trading session, 3.97 million Intra-Cellular Therapies Inc (NASDAQ:ITCI) shares changed hands as the company’s beta touched 0.62. With the company’s most recent per share price at $126.90 changing hands around $0.01 or 0.01% at last look, the market valuation stands at $13.48B. ITCI’s current price is a discount, trading about -0.87% off its 52-week high of $128.00. The share price had its 52-week low at $62.78, which suggests the last value was 50.53% up since then. When we look at Intra-Cellular Therapies Inc’s average trading volume, we note the 10-day average is 6.01 million shares, with the 3-month average coming to 1.45 million.
Analysts gave the Intra-Cellular Therapies Inc (ITCI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.14. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ITCI as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Intra-Cellular Therapies Inc’s EPS for the current quarter is expected to be -0.11.
Intra-Cellular Therapies Inc (NASDAQ:ITCI) trade information
Instantly ITCI is in green as seen in intraday trades today. With action 52.47%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 51.94%, with the 5-day performance at 52.47% in the green. However, in the 30-day time frame, Intra-Cellular Therapies Inc (NASDAQ:ITCI) is 52.16% up. Looking at the short shares, we see there were 1.98 million shares sold at short interest cover period of 4.22 days.
The consensus price target for the stock as assigned by Wall Street analysts is 103, meaning bulls need a downside of -23.2% from its recent market value. According to analyst projections, ITCI’s forecast low is 79 with 132 as the target high. To hit the forecast high, the stock’s price needs a -4.02% plunge from its current level, while the stock would need to tank 37.75% for it to hit the projected low.
Intra-Cellular Therapies Inc (ITCI) estimates and forecasts
Data shows that the Intra-Cellular Therapies Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 61.51% over the past 6 months, a 56.16% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 45.49% up from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 193.96M. 8 analysts are of the opinion that Intra-Cellular Therapies Inc’s revenue for the current quarter will be 198.78M. The company’s revenue for the corresponding quarters a year ago was 132.1M and 144.87M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 46.83%. The estimates for the next quarter sales put growth at 37.22%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 12.47%. The 2025 estimates are for Intra-Cellular Therapies Inc earnings to increase by 57.40%.
ITCI Dividends
Intra-Cellular Therapies Inc is expected to release its next quarterly earnings report in February.
Intra-Cellular Therapies Inc (NASDAQ:ITCI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.33% of Intra-Cellular Therapies Inc shares while 96.05% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 98.34%. There are 96.05% institutions holding the Intra-Cellular Therapies Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 11.6003% of the shares, roughly 11.24 million ITCI shares worth $769.68 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.9168% or 9.61 million shares worth $657.98 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund. With 3.21 shares estimated at $407.85 million under it, the former controlled 3.03% of total outstanding shares. On the other hand, Fidelity Growth Company Fund held about 2.59% of the shares, roughly 2.75 shares worth around $349.19 million.
